{"id":"albumin-human","_fda":{"id":"85f1cecd-a23d-498f-adfb-0a09feed1994","set_id":"167f48d0-8ae5-4f7e-b050-9673dad78acc","openfda":{"unii":["ZIF514RVZR"],"route":["INTRAVENOUS"],"rxcui":["2054168","2054170","2054173","2054174"],"spl_id":["85f1cecd-a23d-498f-adfb-0a09feed1994"],"brand_name":["ALBUMINEX"],"spl_set_id":["167f48d0-8ae5-4f7e-b050-9673dad78acc"],"package_ndc":["64208-2512-8","64208-2512-7","64208-2512-4","64208-2512-3"],"product_ndc":["64208-2512"],"generic_name":["ALBUMIN HUMAN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ALBUMIN HUMAN"],"manufacturer_name":["BPL"],"application_number":["BLA125644"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Risk Summary There are no data with ALBUMINEX 25% use in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted using ALBUMINEX 25%. It is not known whether ALBUMINEX 25% can cause fetal harm when administered to a pregnant woman or can affect fertility. ALBUMINEX 25% should be given to a pregnant woman only if clearly needed. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively."],"references":["15 REFERENCES 1. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;3650:2247-2256 2. Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD001319. DOI: 10.1002/14651858.CD001319.pub3 3. Powell-Tuck J, Gosling P, Lobo DN, et al. British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients. BAPEN; 2011. Available from: http://www.bapen.org.uk/pdfs/bapen_pubs/giftasup.pdf (Guideline Ref ID GIFTASUP2011) 4. Rochwerg B, Alhazzani W, Sindi A, et al. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med 2014;161(5):347-355 5. Wiedermann CJ, Joannidis M. Albumin replacement in severe sepsis or septic shock. N Engl J Med 2014;371:83-84 6. Akech S, Gwer S, Idro R, et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 2006; 5:0001-0011 7. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine, 2013; 41(2):580–637 8. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Systemic Reviews 2013, Issue 2.Art. No.CD000567. DOI:10.1002/14651858.CD000567.pub6. 9. Runyon BA. Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. The American Association for the Study of Liver Diseases 2012. http://www.aasld.org/publications/practice-guidelines-0 [accessed 15 April 2016] 10. EASL clinical practise guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397–417 11. Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012;55:1172-1181 12. Sarma MS, Yachha SK, Bhatia V, et al. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease. J Hepatol 2015:63;1126-1132 13. Wiest R, Krag A, Gerbes A. Spontaneous Bacterial Peritonitis. Recent Guidelines and Beyond. Gut 2012; 61(2):297-310 14. Pham TN, Cancio LC, Gibran NS. American Burn Association Practice Guidelines Burn Shock Resuscitation. J Burn Care Res 2008; 29(1): 257-266 15. Bircan Z, Kervancioglu M. Does albumin and furosemide therapy affect plasma volume in nephrotic children? Pediatr Nephrol 2001;16:497-499 16. Dharmaraj R, Hari P, Bagga A, Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol 2009; 24(4):775-782 17. Martin GS, Moss M, Wheeler AP, et al. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 2005;33(8):1681-1687 18. Uhlig C, Pedro L, Silva PL, et al. Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care 2014, 18:R10 http://ccforum.com/content/18/1/R10 [accessed 02 November 2016] 19. Quinlan GJ, Mumby S, Martin GS, et al. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004;32:755–759 20. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta- analysis of postoperative bleeding. Ann Thorac Surg 2001;72(2):527-534 21. Golab HD, Scohy TV, de Jong PL, et al. Relevance of colloid oncotic pressure regulation during neonatal and infant cardiopulmonary bypass: a prospective randomized study. Eur J Cardio-Thor Surg 2011; 39(6):886-891 22. Hanart C, Khalife M, De Villé A, et al. Perioperative volume replacement in children undergoing cardiac surgery: Albumin versus hydroxyethyl starch 130/0.4. Crit Care Med 2009;37 (2): 696-701 DOI: 10.1097/CCM.0b013e3181958c81 23. Loeffelbein F, Zirell U, Benk C, et al. High colloid oncotic pressure priming of cardiopulmonary bypass in neonates and infants: implications on haemofiltration, weight gain and renal function. Eur J Cardio-Thor Surg 2008; 34(3):648-652 24. Oliver WC Jr, Beynen FM, Nuttall GA, et al. Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime. Ann Thor Surg 2003;75(5):1506-1512 25. Yu K, Liu Y, Hei F, et al. Effect of different albumin concentrations in extracorporeal circuit prime on perioperative fluid status in young children. ASAIO Journal 2008; 54(5):463-466 26. German Medical Association. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives. 4th revised and updated edition 2014. http://www.bundesaerztekammer.de/aerzte/medizin-ethik/wissenschaftlicher-beirat/veroeffentlichungen/haemotherapie-transfusionsmedizin/english/ [accessed 15 April 2016]"],"description":["11 DESCRIPTION ALBUMINEX 25% is a sterile, ready-for-use, clear, slightly viscous, almost colorless, yellow, amber or slightly green aqueous solution of human albumin for single dose intravenous infusion. It is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US. The product also contains 130-160 mmol/L of sodium, less than 200 micrograms/L of aluminum and is stabilized with caprylate (0.08 mmol/g albumin) and acetyltryptophanate (0.08 mmol/g albumin) but does not contain any preservative. 12.5 g (50 mL) of ALBUMINEX 25% is oncotically equivalent to 250 mL plasma. 25 g (100 mL) of ALBUMINEX 25% is oncotically equivalent to 500 mL plasma. The vials are closed with a synthetic rubber stopper. The stopper is not made with natural rubber latex. The viral risk from human plasma is minimized by the fractionation process and pasteurization of the albumin solution for 10 hours at 60°C (140°F) in its final container. These processes are effective for both enveloped and non-enveloped viruses. There have been no reports of virus transmission with products manufactured using this combination of processes. Typical reductions of experimental viral loads are shown in Table 1. Table 1: Virus Reduction for Albumin (Human) 25% Mean Reduction Factors (log 10 ) Enveloped Virus Enveloped Virus Enveloped Virus Enveloped Virus Non-Enveloped Virus Non-Enveloped Virus nd: not determined HIV-1: Human Immunodeficiency Virus Type 1 BVDV: Bovine Viral Diarrhoea Virus IBR: Infectious Bovine Rhinotracheitis HAV: Hepatitis A Virus CPV: Canine Parvovirus Manufacturing Step HIV-1 Sindbis BVDV IBR HAV CPV A+1 Precipitation nd 4.1 >3.4 3.4 3.4 3.7 Fraction IV Precipitation >4.6 >7.1 >4.2 >5.7 4.2 6.0 Pasteurization >6.6 >6.2 >4.0 >5.0 4.7 4.2 Overall >11.2 >13.3 >8.2 >10.7 8.9 10.2"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How ALBUMINEX 25% is supplied ALBUMINEX 25%, 25 g/dL in clear Type II glass vials. Strength Grams and fill size NDC carton number NDC vial number 25% 12.5 g in 50 mL 64208-2512-3 64208-2512-4 25% 25 g in 100 mL 64208-2512-7 64208-2512-8 Not all pack sizes may be marketed. Storage and handling Do not store above 30°C (86°F). Keep the vial stored in the outer carton in order to protect from light. Do not freeze. Do not use ALBUMINEX 25% after the expiration date which is stated on the carton and label after \"EXP.\" The expiration date refers to the last day of that month. ALBUMINEX 25% should be inspected visually for particulate matter and discoloration prior to administration. U.S. federal law prohibits dispensing without prescription."],"geriatric_use":["8.5 Geriatric Use No human or animal data. Use only if clearly needed."],"pediatric_use":["8.4 Pediatric Use No human or animal data. Use only if clearly needed."],"effective_time":"20241231","pharmacokinetics":["12.3 Pharmacokinetics Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid compartment. Albumin has a circulating life span of 15-20 days, with a turnover of approximately 15 g per day. The balance between synthesis and breakdown is normally achieved by feedback regulation. Elimination is predominantly intracellular and due to lysosome proteases. In healthy subjects, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion. There is considerable individual variation in the effect of albumin on plasma volume. In some patients, the plasma volume can remain elevated for several hours. In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions are rigors, hypotension/decreased BP, tachycardia/increased heart rate, pyrexia, feeling cold (chills), nausea, vomiting, dyspnea/bronchospasm, rash/pruritus. Stop the infusion if anaphylaxis, with or without shock, is observed. To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma, Inc. at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 General In general, human albumin solutions are well-tolerated and no specific, clinically relevant alterations in organ function or coagulopathy have been substantiated. 26 The most common adverse reactions associated with infusion of human albumin solutions are rigors, hypotension/decreased BP, tachycardia/increased heart rate, pyrexia, feeling cold (chills), nausea, vomiting, dyspnea/bronchospasm, rash/pruritus. Reactions usually resolve when the infusion is slowed or stopped. Anaphylaxis, with or without shock, may occur and in this situation, stop the infusion. 6.2 Clinical Trials Experience No clinical studies were done using ALBUMINEX 25%."],"contraindications":["4 CONTRAINDICATIONS ALBUMINEX 25% is contraindicated in patients with: Hypersensitivity to human albumin or any of the excipients Severe anemia or cardiac failure with normal or increased intravascular volume Hypersensitivity to human albumin or the excipients Severe anemia or cardiac failure with normal or increased intravascular volume"],"description_table":["<table width=\"75%\"><caption>Table 1: Virus Reduction for Albumin (Human) 25%</caption><col width=\"22%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\" colspan=\"7\">Mean Reduction Factors (log<sub>10</sub>)</th></tr><tr><th styleCode=\"Lrule Rrule\" valign=\"middle\" align=\"center\"/><th styleCode=\"Rrule\" valign=\"middle\">Enveloped Virus</th><th styleCode=\"Rrule\" valign=\"middle\">Enveloped Virus</th><th styleCode=\"Rrule\" valign=\"middle\">Enveloped Virus</th><th styleCode=\"Rrule\" valign=\"middle\">Enveloped Virus</th><th styleCode=\"Rrule\" valign=\"middle\">Non-Enveloped Virus</th><th styleCode=\"Rrule\" valign=\"middle\">Non-Enveloped Virus</th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"7\">nd: not determined HIV-1: Human Immunodeficiency Virus Type 1 BVDV: Bovine Viral Diarrhoea Virus IBR: Infectious Bovine Rhinotracheitis HAV: Hepatitis A Virus CPV: Canine Parvovirus</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Manufacturing Step</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">HIV-1</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">Sindbis</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">BVDV</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">IBR</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">HAV</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">CPV</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">A+1 Precipitation</content></td><td styleCode=\"Rrule\">nd</td><td styleCode=\"Rrule\">4.1</td><td styleCode=\"Rrule\">&gt;3.4</td><td styleCode=\"Rrule\">3.4</td><td styleCode=\"Rrule\">3.4</td><td styleCode=\"Rrule\">3.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Fraction IV Precipitation</content></td><td styleCode=\"Rrule\">&gt;4.6</td><td styleCode=\"Rrule\">&gt;7.1</td><td styleCode=\"Rrule\">&gt;4.2</td><td styleCode=\"Rrule\">&gt;5.7</td><td styleCode=\"Rrule\">4.2</td><td styleCode=\"Rrule\">6.0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Pasteurization</content></td><td styleCode=\"Rrule\">&gt;6.6</td><td styleCode=\"Rrule\">&gt;6.2</td><td styleCode=\"Rrule\">&gt;4.0</td><td styleCode=\"Rrule\">&gt;5.0</td><td styleCode=\"Rrule\">4.7</td><td styleCode=\"Rrule\">4.2</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Overall</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">&gt;11.2</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">&gt;13.3</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">&gt;8.2</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">&gt;10.7</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">8.9</content></td><td styleCode=\"Rrule\"><content styleCode=\"bold\">10.2</content></td></tr></tbody></table>"],"drug_interactions":["7 DRUG INTERACTIONS Do not mix ALBUMINEX 25% with blood, blood components, protein hydrolysates, alcoholic solutions or other medicinal products except 0.9% saline or 5% dextrose. However, it can be administered, via a separate IV line, concomitantly with other parenterals."],"how_supplied_table":["<table width=\"65%\"><col width=\"25%\" align=\"center\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Strength</th><th styleCode=\"Rrule\">Grams and fill size</th><th styleCode=\"Rrule\">NDC carton number</th><th styleCode=\"Rrule\">NDC vial number</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">25%</td><td styleCode=\"Rrule\">12.5 g in 50 mL</td><td styleCode=\"Rrule\">64208-2512-3</td><td styleCode=\"Rrule\">64208-2512-4</td></tr><tr><td styleCode=\"Lrule Rrule\">25%</td><td styleCode=\"Rrule\">25 g in 100 mL</td><td styleCode=\"Rrule\">64208-2512-7</td><td styleCode=\"Rrule\">64208-2512-8</td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Human albumin accounts for more than half of the total protein in the plasma and represents about 10% of protein synthesis activity by the liver. Human Albumin 25% has a corresponding hyperoncotic effect. The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Other physiological functions include antioxidant properties, free radical scavenging, and capillary membrane integrity."],"storage_and_handling":["Storage and handling Do not store above 30°C (86°F). Keep the vial stored in the outer carton in order to protect from light. Do not freeze. Do not use ALBUMINEX 25% after the expiration date which is stated on the carton and label after \"EXP.\" The expiration date refers to the last day of that month. ALBUMINEX 25% should be inspected visually for particulate matter and discoloration prior to administration. U.S. federal law prohibits dispensing without prescription."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Human albumin accounts for more than half of the total protein in the plasma and represents about 10% of protein synthesis activity by the liver. Human Albumin 25% has a corresponding hyperoncotic effect. The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Other physiological functions include antioxidant properties, free radical scavenging, and capillary membrane integrity. 12.3 Pharmacokinetics Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid compartment. Albumin has a circulating life span of 15-20 days, with a turnover of approximately 15 g per day. The balance between synthesis and breakdown is normally achieved by feedback regulation. Elimination is predominantly intracellular and due to lysosome proteases. In healthy subjects, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion. There is considerable individual variation in the effect of albumin on plasma volume. In some patients, the plasma volume can remain elevated for several hours. In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate."],"indications_and_usage":["1 INDICATIONS AND USAGE ALBUMINEX 25% is a 25% albumin solution indicated for adults and children : Hypovolemia ( 1.1 ) Ascites ( 1.2 ) Hypoalbuminemia including from burns ( 1.3 ) Acute Nephrosis ( 1.4 ) Acute Respiratory Distress Syndrome (ARDS) ( 1.5 ) Cardiopulmonary Bypass ( 1.6 ) 1.1 Hypovolemia ALBUMINEX 25% is indicated for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate e.g. hypovolemia following shock due to trauma or sepsis, in surgical patients and in other similar conditions with volume deficiency when restoration and maintenance of circulating blood volume is required in both adult and pediatric patients. In pediatric patients to reverse hypovolemia and achieve normal capillary refill time. 1, 2, 3, 4, 5, 6, 7, 8 1.2 Ascites ALBUMINEX 25% is indicated for prevention of central volume depletion and maintenance of cardiovascular function after large volume parencentesis in patients with liver cirrhosis or other chronic liver disease in adults and children. 9, 10, 11, 12 ALBUMINEX 25% infusion plus administration of vasoactive drugs is indicated in the treatment of type I hepatorenal syndrome. 6 For patients with spontaneous bacterial peritonitis ALBUMINEX 25% is indicated as adjuvant treatment to antibiotic therapy. 9, 10, 13 1.3 Hypoalbuminemia Including from Burns ALBUMINEX 25% is indicated in patients with severe burn injury (> 20% total body surface area), but not until at least 12 to 24 hours after the burn, in order to correct protein loss, decrease overall fluid requirements, decrease systemic edema and stabilize cardiovascular hemodynamics without fluid overload (initial resuscitation should be with crystalloids). 8, 14 ALBUMINEX 25% is also indicated in patients with pre- or post-operative hypoproteinemia and for third space protein loss due to infection or burns. 1.4 Acute Nephrosis ALBUMINEX 25% is indicated in patients with acute nephrosis in combination with loop diuretics to reinforce the diuretic therapeutic effect, which is reduced by hypoalbuminemia, and for the correction of reduced oncotic pressure. 15, 16 1.5 Acute Respiratory Distress Syndrome (ARDS) ALBUMINEX 25% is indicated in conjunction with diuretics to correct fluid volume overload associated with ARDS. 17, 18, 19 1.6 Cardiopulmonary Bypass ALBUMINEX 25% is indicated in cardiopulmonary bypass procedures as part of the priming fluids to passivate the synthetic surfaces of the extracorporeal circuit and maintain the patient's colloid oncotic pressure. 20, 21, 22, 23, 24, 25"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Suspicion of allergic or anaphylactic reactions requires immediate discontinuation of the injection and implementation of appropriate medical treatment. ( 5.1 ) Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the patient's volume status. Use with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient. ( 5.2 ) When concentrated albumin is administered, care must be taken to assure adequate hydration of the patient. ( 5.3 ) Assessment of electrolytes, coagulation and hematology parameters, and hemodynamic status when albumin is administered. ( 5.4 ) Do not dilute with sterile water for injection. ( 5.5 ) This product is made from human plasma and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease agent. ( 5.6 ) 5.1 Hypersensitivity Reactions Suspicion of allergic or anaphylactic reactions requires immediate discontinuation of the infusion and implementation of appropriate medical treatment. 5.2 Hypervolemia Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the patient's volume status. At the first clinical signs of cardiovascular overload (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately. Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient. Examples of such conditions are: Decompensated heart failure Hypertension Esophageal varices Pulmonary edema Hemorrhagic diathesis Severe anemia Renal and post-renal anuria 5.3 Laboratory Parameters 20% - 25% human albumin solutions are relatively low in electrolytes compared to 4% - 5% human albumin solutions so if comparatively large volumes are to be replaced, care must be taken to ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets and erythrocytes). 5.4 Clinical Hemodynamics Parameters Colloid-osmotic effect of human albumin 25% is approximately five times that of blood plasma. Therefore, when concentrated albumin is administered, care must be taken to assure adequate hydration of the patient. Patients should be monitored carefully to guard against circulatory overload and hyperhydration. Patients with marked dehydration require administration of additional fluids. The following parameters should be assessed during administration of ALBUMINEX 25%: Arterial blood pressure and pulse rate Central venous pressure Pulmonary artery occlusion pressure Urine output Electrolytes Hematocrit/hemoglobin 5.5 Pre-infusion Preparation ALBUMINEX 25% must not be diluted with sterile water for injection as this may cause hemolysis in recipients. The product can be diluted in an isotonic solution (e.g., 5% dextrose in water or 0.9% sodium chloride) [see Dosage and Administration (2.2) ]. 5.6 Infectious Diseases Albumin is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for ALBUMINEX 25%."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Ensure that patients to be treated with ALBUMINEX 25% are informed of the potential risks and benefits of its use for their clinical condition [see Warnings and Precautions (5) ] . Check that they are not known to be allergic to the product or its excipients [see Contraindications (4) and Description (11) ] . Make them aware of the symptoms of anaphylaxis [see Hypersensitivity (5.1) ]. Make them aware of the symptoms of potential circulatory overload [see Hypervolemia (5.2) Inform patients that because ALBUMINEX 25% is derived from human blood plasma it may contain infectious agents that cause disease (e.g. viruses and, theoretically CJD agent) although the risk of infection from ALBUMINEX 25% has been reduced by the procedures used in donor selection and during manufacture [see Infectious Diseases (5.6) and Description (11) ] ."],"spl_unclassified_section":["Manufactured by: Bio Products Laboratory Ltd., Elstree, Borehamwood, WD6 3BX. United Kingdom Marketed by: Kedrion Biopharma, Inc. Parker Plaza, 400 Kelby Street, Fort Lee, NJ 07024 United States U.S. Licence No: 1811 ALBUMINEX ® is a registered trademark of Bio Products Laboratory Ltd. Version 2"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For intravenous administration only. For intravenous use only. ALBUMINEX 25% may be diluted with 0.9% saline or 5% dextrose (glucose). Dosage and infusion rate should be adjusted to the patient's individual requirements. Indication Dose Hypovolemia Adults: Initial dose of 25 g (including renal dialysis). For acute liver failure: initial dose of 12 to 25 g. ( 2.1 ) Prevention of central volume depletion after paracentesis due to cirrhotic ascites Adults: 8 g for every 1000 mL of ascitic fluid removed. ( 2.1 ) Hypoalbuminemia including from burns Adults: 50 to 75 g For pre- and post-operative hypoproteinemia: 50 to 75 g. For burn therapy after the first 24 h: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL. Third space protein loss due to infection: initial dose of 50 to 100 g. ( 2.1 ) Acute nephrosis Adults: 25 g together with diuretic once a day for 7-10 days. ( 2.1 ) Adult respiratory distress syndrome (ARDS) Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary. ( 2.1 ) Cardiopulmonary bypass procedures Adults: Initial dose of 25 g. ( 2.1 ) 2.1 Dose The concentration of ALBUMINEX 25% used, its dosage, and infusion rate should be adjusted to the patient's individual requirements and clinical indication. Indication Dose Hypovolemia Hypovolemia Adults: Initial dose of 25 g. If hemodynamic stability is not achieved within 15 to 30 minutes, an additional dose may be given. For acute liver failure: initial dose of 12 to 25 g. An infusion rate of 1-2 mL per minute is usually indicated. For renal dialysis; the initial dose should not exceed 25 g and patients should be carefully observed for signs of fluid overload. Prevention of central volume depletion after paracentesis due to cirrhotic ascites Adults: 8 g for every 1000 mL of ascitic fluid removed. Hypoalbuminemia including from burns Adults: 50 to 75 g For pre- and post-operative hypoproteinemia: 50 to 75 g. In burns, therapy usually starts with administration of large volumes of crystalloid solution to maintain plasma volume. After 24 hours: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g per 100 mL. Third space protein loss due to infection or burns: initial dose of 50 to 100 g. An infusion rate of 1-2 mL per minute is usually indicated in the absence of shock. Treatment should always be guided by hemodynamic response. Acute nephrosis Adults: 25 g together with diuretic once a day for 7-10 days Adult respiratory distress syndrome (ARDS) Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary. Cardiopulmonary bypass procedures Adults: Initial dose of 25 g. Additional amounts may be administered as clinically indicated. 2.3 Administration Visually inspect the solution for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if there are any particulates seen or if the solution is discolored. If a large volume is infused, ensure that the vial is at room temperature before infusion. Do not dilute with Sterile Water for Injection as hemolysis may occur. ALBUMINEX 25% may be diluted with 0.9% saline or 5% dextrose. Begin the infusion within 4 hours of piercing the vial stopper (the product does not contain any preservative). Adjust the rate of infusion according to the individual patient's hemodynamic and other physiological responses, using appropriate clinical monitoring."],"spl_product_data_elements":["ALBUMINEX Albumin Human Albumin Human Albumin Human Sodium Chloride Sodium Hydroxide Caprylic Acid N-ACETYL-DL-TRYPTOPHAN SODIUM"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS ALBUMINEX 25% is a sterile, aqueous solution of human albumin (25% w/v i.e. 25 g/dL) for intravenous administration available as: 50 mL (12.5 g) single dose vial 100 mL (25 g) single dose vial ALBUMINEX 25% is a solution for infusion: ALBUMINEX 25% contains 25 g per dL of human albumin 50 mL (12.5 g) and 100 mL (25 g) glass vials"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no data with ALBUMINEX 25% use in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted using ALBUMINEX 25%. It is not known whether ALBUMINEX 25% can cause fetal harm when administered to a pregnant woman or can affect fertility. ALBUMINEX 25% should be given to a pregnant woman only if clearly needed. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. 8.2 Lactation Risk Summary There is no information regarding the presence of ALBUMINEX 25% in human milk, the effects on the breast-fed infant, or the effects on milk production. The developmental and health benefits of breast-feeding should be considered along with the mother's clinical need for ALBUMINEX 25% and any potential adverse effects on the breast-fed infant from ALBUMINEX 25% or from the underlying maternal condition. 8.4 Pediatric Use No human or animal data. Use only if clearly needed. 8.5 Geriatric Use No human or animal data. Use only if clearly needed."],"dosage_and_administration_table":["<table width=\"100%\"><col width=\"45%\" align=\"left\" valign=\"top\"/><col width=\"55%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Indication</th><th styleCode=\"Rrule\">Dose</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypovolemia</td><td styleCode=\"Rrule\">Adults: Initial dose of 25 g (including renal dialysis). For acute liver failure: initial dose of 12 to 25 g. (<linkHtml href=\"#S2.1\">2.1</linkHtml>)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Prevention of central volume depletion after paracentesis due to cirrhotic ascites</td><td styleCode=\"Rrule\">Adults: 8 g for every 1000 mL of ascitic fluid removed. (<linkHtml href=\"#S2.1\">2.1</linkHtml>)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypoalbuminemia including from burns</td><td styleCode=\"Rrule\">Adults: 50 to 75 g For pre- and post-operative hypoproteinemia: 50 to 75 g. For burn therapy after the first 24 h: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL. Third space protein loss due to infection: initial dose of 50 to 100 g. (<linkHtml href=\"#S2.1\">2.1</linkHtml>)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Acute nephrosis</td><td styleCode=\"Rrule\">Adults: 25 g together with diuretic once a day for 7-10 days. (<linkHtml href=\"#S2.1\">2.1</linkHtml>)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"bottom\">Adult respiratory distress syndrome (ARDS)</td><td styleCode=\"Rrule\">Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary. (<linkHtml href=\"#S2.1\">2.1</linkHtml>)</td></tr><tr><td styleCode=\"Lrule Rrule\">Cardiopulmonary bypass procedures</td><td styleCode=\"Rrule\">Adults: Initial dose of 25 g. (<linkHtml href=\"#S2.1\">2.1</linkHtml>)</td></tr></tbody></table>","<table width=\"75%\"><col width=\"30%\" align=\"left\" valign=\"top\"/><col width=\"70%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\" align=\"center\">Indication</th><th styleCode=\"Rrule\" align=\"center\">Dose</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypovolemia</td><td styleCode=\"Rrule\">Hypovolemia Adults: Initial dose of 25 g. If hemodynamic stability is not achieved within 15 to 30 minutes, an additional dose may be given. For acute liver failure: initial dose of 12 to 25 g. An infusion rate of 1-2 mL per minute is usually indicated. For renal dialysis; the initial dose should not exceed 25 g and patients should be carefully observed for signs of fluid overload.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Prevention of central volume depletion after paracentesis due to cirrhotic ascites</td><td styleCode=\"Rrule\">Adults: 8 g for every 1000 mL of ascitic fluid removed.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypoalbuminemia including from burns</td><td styleCode=\"Rrule\">Adults: 50 to 75 g For pre- and post-operative hypoproteinemia: 50 to 75 g. In burns, therapy usually starts with administration of large volumes of crystalloid solution to maintain plasma volume. After 24 hours: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g per 100 mL. Third space protein loss due to infection or burns: initial dose of 50 to 100 g. An infusion rate of 1-2 mL per minute is usually indicated in the absence of shock. Treatment should always be guided by hemodynamic response.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Acute nephrosis</td><td styleCode=\"Rrule\">Adults: 25 g together with diuretic once a day for 7-10 days</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Adult respiratory distress syndrome (ARDS)</td><td styleCode=\"Rrule\">Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary.</td></tr><tr><td styleCode=\"Lrule Rrule\">Cardiopulmonary bypass procedures</td><td styleCode=\"Rrule\">Adults: Initial dose of 25 g. Additional amounts may be administered as clinically indicated.</td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 100 mL Vial Label NDC 64208-2512-8 Albumin (Human) - kjda solution for infusion For intravenous use only Do not use if turbid. Do not begin administration 4 hours after the vial has been pierced. Marketed by: Kedrion Biopharma, Inc, 400 Kelby St., Fort Lee, NJ 07024, United States PRINCIPAL DISPLAY PANEL - 100 mL Vial Label","PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton NDC 64208-2512-7 Albumin (Human) - kjda ALBUMINEX ® 25% 25 g solution for infusion For intravenous use only Rx only 1 vial 100 mL Bio Products Laboratory PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton","PRINCIPAL DISPLAY PANEL - 50 mL Vial Label NDC 64208-2512-4 Albumin (Human) - kjda solution for infusion For intravenous use only Do not use if turbid. Do not begin administration 4 hours after the vial has been pierced. Marketed by: Kedrion Biopharma, Inc, 400 Kelby St., Fort Lee, NJ 07024, United States PRINCIPAL DISPLAY PANEL - 50 mL Vial Label","PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton NDC 64208-2512-3 Albumin (Human) - kjda ALBUMINEX ® 25% 12.5 g solution for infusion For intravenous use only Rx only 1 vial 50 mL Bio Products Laboratory PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton"]},"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"blood","severity":"major","mechanism":" Mixing with blood may cause incompatibility and adverse reactions.","management":"Do not mix ALBUMINEX 25% with blood.","clinicalEffect":"Potential for adverse reactions due to incompatibility."},{"drug":"blood components","severity":"major","mechanism":" Mixing with blood components may cause incompatibility and adverse reactions.","management":"Do not mix ALBUMINEX 25% with blood components.","clinicalEffect":"Potential for adverse reactions due to incompatibility."},{"drug":"protein hydrolysates","severity":"major","mechanism":" Mixing with protein hydrolysates may cause incompatibility and adverse reactions.","management":"Do not mix ALBUMINEX 25% with protein hydrolysates.","clinicalEffect":"Potential for adverse reactions due to incompatibility."},{"drug":"alcoholic solutions","severity":"major","mechanism":" Mixing with alcoholic solutions may cause incompatibility and adverse reactions.","management":"Do not mix ALBUMINEX 25% with alcoholic solutions.","clinicalEffect":"Potential for adverse reactions due to incompatibility."},{"drug":"other medicinal products","severity":"major","mechanism":" Mixing with other medicinal products may cause incompatibility and adverse reactions.","management":"Do not mix ALBUMINEX 25% with other medicinal products except 0.9% saline or 5% dextrose.","clinicalEffect":"Potential for adverse reactions due to incompatibility."}],"commonSideEffects":[{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Chills","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"","severity":"common","organSystem":""},{"effect":"Flushing","drugRate":"","severity":"common","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Hypersensitivity to human albumin or any of the excipients","Severe anemia or cardiac failure with normal or increased intravascular volume"],"seriousAdverseEvents":[{"effect":"Shock","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALBUMIN HUMAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:00:45.316866+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:02:50.572484+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:00:50.897589+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALBUMIN HUMAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:00:51.250077+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:00:44.207969+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:02:42.998307+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:00:44.208000+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Human albumin accounts for more than half of the total protein in the plasma and represents about 10% of protein synthesis activity by the liver. Human Albumin 25% has a corresponding hyperoncotic effect. The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Other physiological f","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:01:07.472182+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bilirubin sequestering agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:00:52.898701+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:01:45.314183+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201451/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:00:52.565634+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The most common adverse reactions are rigors, hypotension/decreased BP, tachycardia/increased heart rate, pyrexia, feeling cold (chills), nausea, vomiting, dyspnea/bronchospasm, rash/pruritus. Stop the infusion if anaphylaxis, with or without shock, is observed. To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma, Inc. at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 General In general, human albumin solutions are well-","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:01:10.393130+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:01:14.359178+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA125644","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:00:44.208008+00:00"}},"_dailymed":{"setId":"57bd6811-8619-11e0-9d78-0800200c9a66","title":"KEDBUMIN (ALBUMIN (HUMAN)) INJECTION, SOLUTION [KEDRION S.P.A]"},"aiSummary":"Albumin Human 25% is a marketed solution used primarily for treating hypovolemia, leveraging its role in maintaining plasma colloid oncotic pressure and stabilizing blood volume. Its key strength lies in its well-established mechanism and essential role in critical care settings, providing a stable and reliable treatment option. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.","mechanism":{"explanation":"Human Albumin 25% works by maintaining the plasma colloid oncotic pressure, which helps stabilize circulating blood volume. It also acts as a carrier for hormones, enzymes, medicinal products, and toxins, and has additional roles in antioxidant activities and maintaining capillary membrane integrity.","oneSentence":"Human Albumin 25% contributes to plasma colloid oncotic pressure and transports various substances, stabilizing blood volume.","technicalDetail":"Albumin accounts for over half of the total protein in plasma and about 10% of protein synthesis by the liver. Its primary physiological function involves contributing to plasma colloid oncotic pressure and serving as a transport protein for various molecules."},"_scrapedAt":"2026-03-28T00:32:51.955Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T07:02:50.572580+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"albumin-human-hypovolemia","name":"Hypovolemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients with hypovolemia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients with hypovolemia","diagnosticRequired":null,"brandNameForIndication":""},{"id":"albumin-human-ascites","name":"Ascites","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and children with ascites due to liver cirrhosis or other chronic liver disease, type I hepatorenal syndrome, and spontaneous bacterial peritonitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and children with ascites due to liver cirrhosis or other chronic liver disease, type I hepatorenal syndrome, and spontaneous bacterial peritonitis","diagnosticRequired":null,"brandNameForIndication":""},{"id":"albumin-human-hypoalbuminemia-including-from","name":"Hypoalbuminemia including from burns","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with severe burn injury, pre- or post-operative hypoproteinemia, and third space protein loss due to infection or burns","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with severe burn injury, pre- or post-operative hypoproteinemia, and third space protein loss due to infection or burns","diagnosticRequired":null,"brandNameForIndication":""},{"id":"albumin-human-acute-nephrosis","name":"Acute Nephrosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute nephrosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute nephrosis","diagnosticRequired":null,"brandNameForIndication":""},{"id":"albumin-human-acute-respiratory-distress-syn","name":"Acute Respiratory Distress Syndrome (ARDS)","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with ARDS","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with ARDS","diagnosticRequired":null,"brandNameForIndication":""},{"id":"albumin-human-cardiopulmonary-bypass","name":"Cardiopulmonary Bypass","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients undergoing cardiopulmonary bypass procedures","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients undergoing cardiopulmonary bypass procedures","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT02199145","phase":"NA","title":"Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-07-17","conditions":"Membranous Nephropathy","enrollment":52},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT06489015","phase":"EARLY_PHASE1","title":"Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Protgen Ltd","startDate":"2024-06-28","conditions":"Alzheimer's Disease (AD)","enrollment":30},{"nctId":"NCT05179265","phase":"PHASE1","title":"Recombinant Human Serum Albumin in Healthy Subjects","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2021-03-29","conditions":"Hepatic Ascites","enrollment":48},{"nctId":"NCT05249374","phase":"PHASE1","title":"Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2021-10-14","conditions":"Hepatic Ascites","enrollment":36},{"nctId":"NCT06553456","phase":"PHASE2, PHASE3","title":"Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2024-08-19","conditions":"Cirrhotic Ascites","enrollment":390},{"nctId":"NCT05858853","phase":"PHASE2, PHASE3","title":"Phase II/III of Recombinant Human Serum Albumin","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2023-05-24","conditions":"Cirrhotic Ascites","enrollment":92},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT07449364","phase":"NA","title":"Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient","status":"COMPLETED","sponsor":"Daewoong Group Indonesia","startDate":"2025-03-24","conditions":"Frailty in Older Adults","enrollment":10},{"nctId":"NCT05325632","phase":"PHASE2","title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-28","conditions":"HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT07435922","phase":"","title":"Evaluate Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment","status":"NOT_YET_RECRUITING","sponsor":"Healthgen Biotechnology Corp.","startDate":"2026-02-24","conditions":"Hypoalbuminemia, Hypovolemia","enrollment":2000},{"nctId":"NCT04104672","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2019-11-06","conditions":"Advanced Pancreatic Cancer","enrollment":196},{"nctId":"NCT05580601","phase":"PHASE1, PHASE2","title":"Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-05-05","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07408583","phase":"PHASE1, PHASE2","title":"Prenatal Transplantation for Fetuses With Fanconi Anemia","status":"NOT_YET_RECRUITING","sponsor":"Agnieszka Czechowicz","startDate":"2026-07","conditions":"Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes","enrollment":12},{"nctId":"NCT04892953","phase":"PHASE2","title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8","enrollment":51},{"nctId":"NCT07415655","phase":"PHASE2","title":"Modulation of Cerebral Ischemia by Albumin","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Hradec Kralove","startDate":"2026-02-03","conditions":"Ischemic Stroke","enrollment":100},{"nctId":"NCT05722938","phase":"PHASE3","title":"Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)","status":"RECRUITING","sponsor":"Biotest","startDate":"2023-09-09","conditions":"Community-acquired Pneumonia","enrollment":590},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT05208242","phase":"PHASE2, PHASE3","title":"Strong Albumin Solutions in Patients With Septic Shock","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2023-11-10","conditions":"Sepsis, Septic Shock, Shock, Toxic","enrollment":47},{"nctId":"NCT05857371","phase":"PHASE2","title":"Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-03-13","conditions":"Urethral Stenosis","enrollment":20},{"nctId":"NCT05352750","phase":"PHASE1","title":"Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sonnet BioTherapeutics","startDate":"2022-04-20","conditions":"Advanced Solid Tumor, Soft Tissue Sarcoma Adult","enrollment":42},{"nctId":"NCT06528093","phase":"PHASE1","title":"A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2024-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":8},{"nctId":"NCT05056220","phase":"PHASE3","title":"Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites","status":"RECRUITING","sponsor":"Aleksander Krag","startDate":"2024-02-26","conditions":"Decompensated Cirrhosis and Ascites","enrollment":240},{"nctId":"NCT02922413","phase":"PHASE2","title":"Panhematin for Prevention of Acute Attacks of Porphyria","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2015-10-30","conditions":"Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria","enrollment":13},{"nctId":"NCT07371624","phase":"PHASE1, PHASE2","title":"A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.","status":"RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2025-12-31","conditions":"Acute Ischemic Stroke","enrollment":54},{"nctId":"NCT07263308","phase":"PHASE3","title":"Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-12-18","conditions":"Acute Ischemic Stroke","enrollment":1192},{"nctId":"NCT07365475","phase":"PHASE2","title":"Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Huanhu Hospital","startDate":"2026-01-30","conditions":"Acute Ischemic Stroke From Large Vessel Occlusion","enrollment":306},{"nctId":"NCT07349342","phase":"NA","title":"Stable Versus Unstable Resistance Training Effects on Physical Fitness and Physiological Biomarkers of Untrained Male University Students","status":"ACTIVE_NOT_RECRUITING","sponsor":"Addis Ababa University","startDate":"2025-11-12","conditions":"No Condition, Health Young Males","enrollment":54},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT01783288","phase":"NA","title":"Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2013-02","conditions":"Postural Tachycardia Syndrome","enrollment":110},{"nctId":"NCT03265808","phase":"PHASE1, PHASE2","title":"Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.","status":"COMPLETED","sponsor":"Ihsan M Salloum, MD, MPH","startDate":"2018-03-18","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":31},{"nctId":"NCT03181100","phase":"PHASE2","title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-27","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT07320430","phase":"NA","title":"Comparative Study Between Sclerosing Agents Used in Treatment of Vascular Malformation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-02-14","conditions":"Vascular Malformation","enrollment":75},{"nctId":"NCT07020715","phase":"PHASE2","title":"A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2026-03-01","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT07299253","phase":"EARLY_PHASE1","title":"Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06","status":"COMPLETED","sponsor":"Lanzhou University Second Hospital","startDate":"2023-08-16","conditions":"Metastatic Solid Tumors (Any Localization)","enrollment":5},{"nctId":"NCT07294391","phase":"PHASE2","title":"The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Huanhu Hospital","startDate":"2025-12-10","conditions":"Acute Ischemic Stroke From Large Vessel Occlusion","enrollment":60},{"nctId":"NCT07236736","phase":"NA","title":"Evaluation of SPM™ Topical Cosmetic Application on Skin Appearance, Hydration, and Barrier Support in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Biocoz Global Pte. Ltd.","startDate":"2026-01-30","conditions":"Healthy Skin, Skin Hydration","enrollment":10},{"nctId":"NCT07270874","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2026-01","conditions":"Decompensated Cirrhosis, AKI - Acute Kidney Injury","enrollment":114},{"nctId":"NCT06492759","phase":"PHASE2","title":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-01-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":29},{"nctId":"NCT03702920","phase":"PHASE3","title":"Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2019-02-21","conditions":"Acute-On-Chronic Liver Failure","enrollment":275},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":"Pancreatic Cancer","enrollment":328},{"nctId":"NCT07071337","phase":"PHASE3","title":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2025-07-18","conditions":"Metastatic Breast Cancer","enrollment":430},{"nctId":"NCT05623111","phase":"PHASE2","title":"Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-08-01","conditions":"Diabetic Neuropathy, Painful","enrollment":80},{"nctId":"NCT04044690","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2019-10-21","conditions":"Dermatomyositis","enrollment":134},{"nctId":"NCT06535945","phase":"PHASE4","title":"Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2025-03-26","conditions":"Liver Transplantation, Acute Kidney Injury","enrollment":400},{"nctId":"NCT03818854","phase":"PHASE2","title":"Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Michael A. Matthay","startDate":"2019-11-26","conditions":"Respiratory Distress Syndrome, Adult","enrollment":120},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT04057833","phase":"PHASE1","title":"E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-11-20","conditions":"Rotator Cuff Tears, Muscle Atrophy or Weakness, Tendon Rupture - Shoulder","enrollment":20},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT07212582","phase":"PHASE3","title":"Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)","status":"NOT_YET_RECRUITING","sponsor":"Mahidol University","startDate":"2025-12-01","conditions":"Critical Illness, Septic Shock","enrollment":304},{"nctId":"NCT05630183","phase":"PHASE2","title":"A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agenus Inc.","startDate":"2023-03-27","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":81},{"nctId":"NCT02725060","phase":"NA","title":"Autoimmune Basis for Postural Tachycardia Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2016-02","conditions":"Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia","enrollment":58},{"nctId":"NCT06675136","phase":"PHASE1","title":"Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-29","conditions":"Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":30},{"nctId":"NCT02346747","phase":"PHASE2","title":"A Trial of Vigil for Participants With Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gradalis, Inc.","startDate":"2015-02","conditions":"Ovarian Cancer, Ovarian Neoplasms","enrollment":92},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT04940286","phase":"PHASE2","title":"Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-28","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8","enrollment":13},{"nctId":"NCT00608725","phase":"NA","title":"Pathophysiology of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1996-12","conditions":"Tachycardia, Postural Orthostatic Tachycardia Syndrome","enrollment":260},{"nctId":"NCT03734029","phase":"PHASE3","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":557},{"nctId":"NCT05840211","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-08","conditions":"Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":654},{"nctId":"NCT05867602","phase":"PHASE2","title":"High Dose Albumin in Refractory Ascites","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2019-03-25","conditions":"Ascites","enrollment":100},{"nctId":"NCT03461900","phase":"NA","title":"Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2019-06-04","conditions":"Septic Shock","enrollment":535},{"nctId":"NCT04216784","phase":"PHASE4","title":"Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2019-12-19","conditions":"Cirrhosis, Liver, Volume Overload, Fluid Overload","enrollment":21},{"nctId":"NCT03211793","phase":"PHASE1, PHASE2","title":"Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2021-10-06","conditions":"Systemic Sclerosis, Digital Ulcer","enrollment":20},{"nctId":"NCT05854641","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":"Critical Limb Ischemia, Peripheral Arterial Disease","enrollment":10},{"nctId":"NCT05854615","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":"Critical Limb Ischemia, Buerger's Disease","enrollment":3},{"nctId":"NCT04869397","phase":"PHASE2","title":"Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-14","conditions":"Covid19","enrollment":19},{"nctId":"NCT06934473","phase":"NA","title":"Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals","status":"RECRUITING","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2025-05-21","conditions":"Bloodpressure","enrollment":16},{"nctId":"NCT02219165","phase":"PHASE2","title":"Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-01-08","conditions":"Toxic Shock Syndrome","enrollment":30},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Overt Hepatic Encephalopathy","enrollment":174},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT00936819","phase":"PHASE2","title":"The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-07-19","conditions":"Anterior Wall Myocardial Infarction","enrollment":47},{"nctId":"NCT07119463","phase":"PHASE2","title":"Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2024-10-29","conditions":"Postoperative Hypoalbuminemia, Postoperative Complications, Gastric Cancer","enrollment":112},{"nctId":"NCT06524739","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2024-08-28","conditions":"Post-COVID Postural Orthostatic Tachycardia Syndrome","enrollment":16},{"nctId":"NCT04865107","phase":"PHASE2","title":"Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-04-27","conditions":"Covid19, Acute Respiratory Distress Syndrome","enrollment":22},{"nctId":"NCT06299163","phase":"PHASE1","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","status":"TERMINATED","sponsor":"Numab Therapeutics AG","startDate":"2024-05-01","conditions":"Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma","enrollment":11},{"nctId":"NCT05239182","phase":"PHASE2","title":"9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Anwaar Saeed","startDate":"2022-01-26","conditions":"Pancreatic Adenocarcinoma","enrollment":7},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT00199862","phase":"NA","title":"Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-02","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Tumor","enrollment":30},{"nctId":"NCT05148286","phase":"PHASE4","title":"Albumin and Crystalloid Administration in Septic Shock","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-01-17","conditions":"Septic Shock","enrollment":2426},{"nctId":"NCT06500208","phase":"PHASE2","title":"Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-01","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT05451043","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-07-05","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer","enrollment":62},{"nctId":"NCT06394661","phase":"PHASE2","title":"Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-04-28","conditions":"Breast Cancer","enrollment":109},{"nctId":"NCT06781281","phase":"","title":"NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-12-04","conditions":"Breast Cancer Invasive","enrollment":709},{"nctId":"NCT00868530","phase":"PHASE3","title":"Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Hemophilia A","enrollment":53},{"nctId":"NCT05531149","phase":"PHASE3","title":"Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia","status":"TERMINATED","sponsor":"Biotest","startDate":"2022-12-22","conditions":"Respiratory Infection, Pneumonia, Community-acquired Pneumonia","enrollment":107},{"nctId":"NCT03451292","phase":"PHASE3","title":"Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2018-07-24","conditions":"Decompensated Cirrhosis and Ascites","enrollment":410},{"nctId":"NCT05937048","phase":"NA","title":"Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-07-30","conditions":"Decompensated Cirrhosis","enrollment":120},{"nctId":"NCT04442126","phase":"PHASE1, PHASE2","title":"A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Numab Therapeutics AG","startDate":"2020-08-19","conditions":"Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":52},{"nctId":"NCT05775211","phase":"NA","title":"Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations","status":"RECRUITING","sponsor":"Nadezhda Women's Health Hospital","startDate":"2023-03-13","conditions":"Infertility","enrollment":300},{"nctId":"NCT05775198","phase":"NA","title":"Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome","status":"RECRUITING","sponsor":"Nadezhda Women's Health Hospital","startDate":"2023-03-01","conditions":"Infertility, Female, IVF","enrollment":300},{"nctId":"NCT06654687","phase":"NA","title":"Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Cesarean Delivery Under Spinal Anesthesia","status":"COMPLETED","sponsor":"Sameh Fathy","startDate":"2024-10-27","conditions":"Pregnancy, Cesarean Delivery, Spinal Anesthesia Induced Hypotension","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Intravenous"},"crossReferences":{"chemblId":"CHEMBL1201451"},"_approvalHistory":[],"publicationCount":194,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"ALBUMIN HUMAN","genericName":"ALBUMIN HUMAN","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T07:02:50.572580+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}